Press Releases

Read our latest announcements

Filter by year:

2017-06-14
The Board of Directors’ Proposed Resolution Regarding Issue of Warrants

I händelse av skillnad mellan den engelska och svenska versionen av detta protokoll ska den svenska versionen gälla. In case of any discrepancy between the English and Swedish language versions of these minutes, the Swedish language version shall prevail. Styrelsens förslag till beslut om emission av teckningsoptioner The board of directors’ proposed resolution regarding issue […]

View Press Release
Annual Shareholders Meeting Update (in Swedish)

I händelse av skillnad mellan den engelska och svenska versionen av detta protokoll ska den svenska versionen gälla. In case of any discrepancy between the English and Swedish language versions of these minutes, the Swedish language version shall prevail. _________________________________________________________________________ VILLKOR FÖR TECKNINGSOPTIONER SERIE 2017/2020 I MODUS THERAPEUTICS HOLDING AB Terms and conditions for warrants […]

View Press Release
2017-05-24
Notice of Annual General Meeting of Modus Therapeutics Holding AB (publ) (in Swedish)

Kallelse till Årsstämma i Modus Therapeutics Holding AB (publ) Aktieägarna i årsstämma i Modus Therapeutics Holding AB (publ), org. nr 556851-9523 (”Bolaget”), kallas till årsstämma i Setterwalls Advokatbyrås lokaler med adress Sturegatan 10, Stockholm onsdagen den 28 juni 2017 kl. 16.00. Förutsättningar för deltagande Aktieägare som önskar delta vid årsstämman ska vara införd i Bolagets […]

View Press Release
2017-04-24
Modus Therapeutics appoints Ellen K. Donnelly, Ph.D. as CEO

STOCKHOLM, SWEDEN – 24 April, 2017. Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle cell disease (SCD), announces the appointment of Ellen K. Donnelly, Ph.D as Chief Executive Officer. Modus Therapeutics’ lead drug candidate sevuparin is currently in a Phase II clinical trial in patients with […]

View Press Release
2017-02-20
Modus Therapeutics raises SEK 32 million to support further development of sevuparin for sickle cell disease

STOCKHOLM, SWEDEN – 20 February, 2017. Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle cell disease, announces the successful completion of a financing round raising SEK 32 million from existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest.  Modus Therapeutics is currently recruiting patients in Europe, the Middle East and […]

View Press Release